Document is current
Any future updates will be listed below
-
Authors
Kadirvelu, Balasundaram
Gavriel, Constantinos
Nageshwaran, Sathiji
Chan, Jackson Ping Kei
Nethisinghe, Suran http://orcid.org/0000-0002-4272-9292
Athanasopoulos, Stavros http://orcid.org/0000-0003-0421-0227
Ricotti, Valeria http://orcid.org/0000-0003-1800-1987
Voit, Thomas http://orcid.org/0000-0002-7424-5401
Giunti, Paola
Festenstein, Richard
Faisal, A. Aldo http://orcid.org/0000-0003-0813-7207
-
Funding
Funding for this research was provided by:
UKRI Turing AI Fellowship
- License Information
-
More Information
Article History
Received: 20 July 2021
Accepted: 29 November 2022
First Online: 19 January 2023
Competing interests
: A.A.F. has consulted in the domain of AI for Airbus and Celestial Group. He received research funding paid to his institution from Fresenius-KABI, Shell, Airbus. He received donations given to his institution from Facebook, NVIDIA and Microsoft. RF has consulted for Pfizer and has received funding but not related to this study. VR was a Solid Biosciences employee at the time of the conduct of the study. Currently, VR is cofounder EVP, CMO and stockholder of DiNAQOR AG, the products of which are not related to this study. TV was a consultant for Antisense Therapeutics, BioPhytis, Catabasis, DZHK, Italfarmaco, Santhera, Sarepta, Servier, Syneos Health, Solid Biosciences. TV is a SAB member and stockholder of Constant Pharmaceuticals and a cofounder, CSO and stockholder of DiNAQOR AG. AF, RF, TV, and VR are coinventors of an International Patent Application PCT/EP2020/077703—’systems and methods for monitoring the state of a disease using a biomarker’. The remaining authors have no competing interests.
